UF Health Neurology AAN Annual Meeting participation

Check out UF Health’s involvement in the AAN Annual Meeting, a week-long event that will be held at the Pennsylvania Convention Center in Philadelphia. The gathering “offers innovative, unique, and creative experiences throughout the week served up in exciting and inspirational formats to fuel your mind, body, and spirit.”

American Academy of Neurology Annual Meeting (May 4-10th 2019)

  • Kenneth M. Heilman, MD, FAAN
    • Event – HeadTalks – Standing on the Shoulders of Giants (May 6th 5 p.m. – 6 p.m.)
    • Poster session – Impact of Educational Inequality on Incidence of Post-stroke Vascular Mild Cognitive Impairment – Application of the Previous Study on Stratified Education-adjusted MoCA Assessment (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Using the Montreal Cognitive Assessment (MoCA): to Predict Three Month Recovery Following a Stroke (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Left hemispatial neglect with a splenial lesion (May 7th 11:30 a.m. – 6:30 p.m.)
  • Melissa Armstrong, MD
    •  Poster session – Lewy body dementia (LBD) prevalence and cholinesterase inhibitor use in Florida (May 8th 11:30 a.m. – 6:30 p.m.)
    • Event – Aging, Dementia, Cognitive and Behavioral Neurology (May 9th 7 p.m. – 10 p.m.)
  • Aaron Carlson, MD
    • Poster session – Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Not Responsive to Steroids – Management Decisions in a Situation of Diagnostic Uncertainty (May 6th 11:30 a.m. – 6:30 p.m.)
  • Miguel Chuquilin, MD
    • Poster session – Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation: Two Siblings with A Novel Mutation in The DARS2 Gene (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Neurological and neuroscience education: mitigating neurophobia to mentor healthcare providers (May 7th 11:30 a.m. – 6:30 p.m.)
  • Irene Malaty, MD
    • Poster session – Diagnosis and Treatment Experiences in a Real-World Sample of Tourette Syndrome and Tic Disorder Sufferers (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Self-Reported Substance Use in a Real-World Sample of Subjects with Tourette Syndrome and Other Tic Disorder (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – The Impact of Tourette Syndrome and Tic Disorders on Education, Occupational, and Personal Life (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – TANGO2 Mutation: A Novel Cause of Movement Disorders
  • Wissam Deeb, MD
    • Poster session – Dorsal GPi/GPe DBS Induced Dyskinesia (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Diagnosis and Treatment Experiences in a Real-World Sample of Tourette Syndrome and Tic Disorder Sufferers (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Self-Reported Substance Use in a Real-World Sample of Subjects with Tourette Syndrome and Other Tic Disorder (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – The Impact of Tourette Syndrome and Tic Disorders on Education, Occupational, and Personal Life (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Development of an EMG Based Tic Detector (May 8th 11:30 a.m. – 6:30 p.m.)
  • Kelly Foote, MD
    • Poster session – Longitudinal outcomes of LRRK2 gene mutation parkinsonism undergoing either Subthalamic Nucleus (STN) or Globus Pallidus Internus (GPi) Deep-Brain stimulation (DBS): a multi-group comparison (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Dorsal GPi/GPe DBS Induced Dyskinesia (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Longitudinal follow-up of deal-lead thalamic deep brain stimulation for patients with treatment refractory multiple sclerosis tremor (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Outcomes with VIM deep brain stimulation in dystonic tremor versus essential tremor (May 8th 11:30 a.m. – 6:30 p.m.)
  • Michael Okun, MD
    • Poster session – Longitudinal outcomes of LRRK2 gene mutation parkinsonism undergoing either Subthalamic Nucleus (STN) or Globus Pallidus Internus (GPi) Deep-Brain stimulation (DBS): a multi-group comparison (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Dorsal GPi/GPe DBS Induced Dyskinesia (May 5th 11:30 a.m. – 6:30 p.m.)
    • Event – C117 – Tourette Syndrome: Assessment and Management (May 6th 3:30 p.m. – 5:30 p.m.)
    • Event – C155 Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders (May 7th 3:30 p.m. – 5:30 p.m.)
    • Poster session – Development of an EMG Based Tic Detector (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Longitudinal follow-up of deal-lead thalamic deep brain stimulation for patients with treatment refractory multiple sclerosis tremor (May 8th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Outcomes with VIM deep brain stimulation in dystonic tremor versus essential tremor (May 8th 11:30 a.m. – 6:30 p.m.)
    • Event – C209 – Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson’s Disease (May 9th 7 a.m. – 9 a.m.)
  • Aysegul Gunduz, PhD
    • Poster session – Development of an EMG Based Tic Detector (May 8th 11:30 a.m. – 6:30 p.m.)
  • Trisham Gyang, MD
    • Poster session – Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Not Responsive to Steroids – Management Decisions in a Situation of Diagnostic Uncertainty (May 6th 11:30 a.m. – 6:30 p.m.)
  • Jacqueline Baron-Lee, PhD
    • Poster session – Lack of Standardization of the Level of Encephalopathy on EEG: a Barrier to the Widespread Use of EEG for Brain Monitoring (May 8th 11:30 a.m. – 6:30 p.m.)
  • Carolina Maciel, MD
    • Poster session – Lack of Standardization of the Level of Encephalopathy on EEG: a Barrier to the Widespread Use of EEG for Brain Monitoring (May 8th 11:30 a.m. – 6:30 p.m.)
  • Nikolaus McFarland, PhD, MD
    • Poster session – Prevalence estimates and clinical characterization for tremor and dystonia in Progressive Supranuclear Palsy (May 7th 11:30 a.m. – 6:30 p.m.)
    • Poster session – RabGTPase Expression Changes in a-Synucleinopathy and Tauopathy Disorders (May 7th 11:30 a.m. – 6:30 p.m.)
  • Adolfo Ramirez-Zamora, MD
    • Poster session – Correlation of Electrode Location and Outcomes of Gait and Axial Function in Parkinson’s Disease Patients managed with Subthalamic Deep Brain Stimulation (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Dorsal GPi/GPe DBS Induced Dyskinesia (May 5th 11:30 a.m. – 6:30 p.m.)
  • Christopher P. Robinson, DO
    • Poster session – Brain eating Balamuthia amoebic infection – A Case Report (May 9th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Variability In Reported Physician Practices For Brain Death Determination (May 9th 11:30 a.m. – 6:30 p.m.)
  • Aparna Wagle Shukla, MD
    • Poster session – Prevalence estimates and clinical characterization for tremor and dystonia in Progressive Supranuclear Palsy (May 7th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Outcomes with VIM deep brain stimulation in dystonic tremor versus essential tremor (May 8th 11:30 a.m. – 6:30 p.m.)
  • Alexis Simpkins, MD, PhD
    • Scientific session (*defined below*) – Novel Transcripts miR-1301, miR-130, and miR-629 Influence Early Neurologic Outcome in Acute Ischemic Stroke Patients (May 6th 3:41 p.m.)
  • S.H. Subramony, MD
    • Scientific session **Abstract of Distinction** – Results of the Dose-Escalation Portion of a Phase 2 Study of ACE-083, a Local Muscle Therapeutic, in Patients with Charcot-Marie-Tooth (CMT) Disease (May 10th 1:55 p.m.)
    • Poster session – The impact of ethnicity on the phenotype of a monogenetic disorder: spinocerebellar ataxias type 3 (May 5th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Variant of Uncertain Significance in Charcot Marie Tooth Disease: GDAP1 Protein Modeling and Phenotype Correlation (May 7th 11:30 a.m. – 6:30 p.m.)
    • Poster session – Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor (May 8th 11:30 a.m. – 6:30 p.m.)
  • H. Lee Sweeney, PhD
    • Scientific session – Edasalonexent, an NF-kB Inhibitor, Slows Longer-Term Disease Progression on Multiple Functional and MRI Assessments Compared to Control Period in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy (May 9th 4:25 p.m.)
  • Krista H. Elvire Vandenborne, PT, PhD
    • Scientific session – Edasalonexent, an NF-kB Inhibitor, Slows Longer-Term Disease Progression on Multiple Functional and MRI Assessments Compared to Control Period in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy (May 9th 4:25 p.m.)
  • James P. Wymer, MD, PhD, CPI, FAAN
    • Scientific session – General Characteristics of edaravone Use in the Natural History of ALS and Other Motor Neuron Disorders Consortium Dataset (NeuroBANKTM) (May 5th 1:55 p.m.)
  • Pam Zeilman, ARNP
    • Poster session – Longitudinal follow-up of deal-lead thalamic deep brain stimulation for patients with treatment refractory multiple sclerosis tremor (May 8th 11:30 a.m. – 6:30 p.m.)